Eravacycline
- Generic Name
- Eravacycline
- Brand Names
- Xerava
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31FN4O8
- CAS Number
- 1207283-85-9
- Unique Ingredient Identifier
- 07896928ZC
- Background
Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .
- Indication
Eravacycline is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older .
- Associated Conditions
- Intraabdominal Infections
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 908
- Registration Number
- NCT01978938
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Columbus Regional Research Institute, Columbus, Ohio, United States
🇨🇿Thomayer Hospital, Department of Urology, Prague, Czechia
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 541
- Registration Number
- NCT01844856
Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections
- Conditions
- Complicated Intra-abdominal Infection
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01265784
- Locations
- 🇧🇬
MHAT "Russe" AD, Russe, Russe, Bulgaria
🇺🇸Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸Long Beach VA Medical Center, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.